GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives
This article was originally published in The Pink Sheet Daily
Executive Summary
The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.